NEWLINK GENETICS CORPORATION | 16,087 Euro | +0,346 +2,20 % | |
| WKN: A1JH4X ISIN: US6515111077 Ticker-Symbol: 4NX | Frankfurt | 19.06.13 | 17:09 Uhr |
Branche BiotechnologieAktienmarkt NASDAQ Biotech |
|
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 13.06. | New Research Grants, Product Launches, and Positive Clinical Study Results - Research Report on Boston Scientific, Cooper, Arena Pharmaceuticals, Apricus Biosciences, and NewLink Genetics | 27 | PR Newswire | |
| NEW YORK, June 13, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Wall Street Reports announced new research reports highlighting Boston... Mehr lesen zu: New Research Grants, Product Launches, and Positive Clinical Study Results - Research Report on Boston Scientific, Cooper, Arena Pharmaceuticals, Apricus Biosciences, and NewLink Genetics | ||||
| 10.06. | Why Did Immunotherapy Pioneer NewLink Genetics Reach A 52-Week High? | 1 | Seeking Alpha | |
| 03.06. | NEWLINK GENETICS CORP - 8-K, Current Report | - | SEC Filings | |
| 03.06. | NewLink Genetics Presents Results from Two Phase 1 Studies with Immunotherapy Agent, Indoximod, at the ASCO 2013 Annual Meeting | 23 | PR Newswire | |
| AMES, Iowa, June 3, 2013 /PRNewswire/ --NewLink Genetics Corporation (NASDAQ: NLNK), an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced results from two clinical... Mehr lesen zu: NewLink Genetics Presents Results from Two Phase 1 Studies with Immunotherapy Agent, Indoximod, at the ASCO 2013 Annual Meeting | ||||
| 03.06. | NewLink Genetics' Algenpantucel-L Shows Encouraging Disease-Free and Overall Survival in Phase 2 Study in Resected Pancreatic Cancer | 21 | PR Newswire | |
| AMES, Iowa, June 3, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced results from a Phase... Mehr lesen zu: NewLink Genetics' Algenpantucel-L Shows Encouraging Disease-Free and Overall Survival in Phase 2 Study in Resected Pancreatic Cancer | ||||
| 01.06. | NewLink Genetics Presents Positive Phase 2 Tergenpumatucel-L Non-Small Cell Lung Cancer Data | 1 | Benzinga.com | |
| 01.06. | NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual Meeting | 101 | PR Newswire | |
| AMES, Iowa, June 1, 2013 /PRNewswire/ --NewLink Genetics Corporation (NASDAQ: NLNK), an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced results from a Phase... Mehr lesen zu: NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual Meeting | ||||
| 29.05. | NewLink Genetics to Present at the Jefferies 2013 Healthcare Conference | 16 | PR Newswire | |
| AMES, Iowa, May 29, 2013 /PRNewswire/ --NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to... Mehr lesen zu: NewLink Genetics to Present at the Jefferies 2013 Healthcare Conference | ||||
| 16.05. | NEWLINK GENETICS CORP - 8-K, Current Report | - | SEC Filings | |
| 06.05. | NEWLINK GENETICS CORP - 8-K, Current Report | 1 | SEC Filings | |
| 29.04. | NewLink Genetics: Looking To Join The Industry's Largest Movers | - | Seeking Alpha | |
| 25.04. | NewLink Genetics to Present at the Needham and Company 12th Annual Healthcare Conference | 33 | PR Newswire | |
| AMES, Iowa, April 25, 2013 /PRNewswire/ --NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company primarily focused on discovering, developing and commercializing immunotherapeutic... Mehr lesen zu: NewLink Genetics to Present at the Needham and Company 12th Annual Healthcare Conference | ||||
| 08.04. | NewLink Genetics Presents Preclinical Data on New IDO Pathway Inhibitor, NLG919, at AACR 2013 Annual Meeting | 25 | PR Newswire | |
| AMES, Iowa, April 8, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company primarily focused on discovering, developing and commercializing... Mehr lesen zu: NewLink Genetics Presents Preclinical Data on New IDO Pathway Inhibitor, NLG919, at AACR 2013 Annual Meeting | ||||
| 04.04. | NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer | 55 | PR Newswire | |
| AMES, Iowa, April 4, 2013 /PRNewswire/ --NewLink Genetics Corporation (NASDAQ: NLNK) is a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics.... Mehr lesen zu: NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer | ||||
| 02.04. | NewLink Genetics (NLNK) Commences Indoximod Phase 2 in Metastatic Breast Cancer | - | StreetInsider.com | |
| 02.04. | NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer | 43 | PR Newswire | |
| AMES, Iowa, April 2, 2013 /PRNewswire/ --NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today... Mehr lesen zu: NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer | ||||
| 28.02. | NewLink Genetics' CEO Discusses Q4 2012 Results - Earnings Call Transcript | - | Seeking Alpha | |
| 25.02. | NewLink Genetics Announces Timing of Fourth Quarter and Year-End 2012 Financial Results Conference Call | 37 | PR Newswire | |
| AMES, Iowa, Feb. 25, 2013 /PRNewswire/ --NewLink Genetics Corporation (Nasdaq:NLNK) today announced that its Fourth Quarter and fiscal year ended December 31, 2012 financial results will be released... Mehr lesen zu: NewLink Genetics Announces Timing of Fourth Quarter and Year-End 2012 Financial Results Conference Call | ||||
| 11.02. | NewLink Genetics Corporation: A Promising Immunotherapy Company With An Upcoming Catalyst | - | Seeking Alpha | |
| 04.02. | NewLink Genetics Corporation Announces Exercise of Underwriters' Option and Closing of Public Offering of Common Stock | 26 | PR Newswire | |
| AMES, Iowa, Feb. 4, 2013 /PRNewswire/ --NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced... Mehr lesen zu: NewLink Genetics Corporation Announces Exercise of Underwriters' Option and Closing of Public Offering of Common Stock | ||||
Seite: 1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| EMERGENT BIOSOLUTIONS | 11,093 | +2,62 % | MdBio Foundation adds Allen Shofe of Emergent BioSolutions to board |
| DYAX | 2,384 | +0,21 % | Biotech Industry Soars in 2012 as FDA Drug Approvals Reach a 15-Year High / RDInvesting Provides Stocks Research on Neuralstem and Dyax |
| STEMCELLS | 1,296 | +2,53 % | StemCells: Health Canada Approves Expansion Of Spine Injury Phase I/II Trial |
| MONSANTO | 78,55 | +0,25 % | Monsanto Company Releases 2012 Sustainability Report |
| LEXICON PHARMACEUTICALS | 1,675 | +3,08 % | Lexicon Pharmaceuticals' Management Presents at 38th Annual dbAccess Health Care Conference (Transcript) |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von